Fragmin Tolerability

Fragmin has been extensively used since its launch in 1992¹

Approximately 3% of the patients receiving prophylactic treatment reported side effects^2-7. Fragmin is an antithrombotic agent that acts mainly through its ability to potentiate the inhibition of Factor Xa and thrombin by antithrombin. Compared with standard, unfractionated heparin, Fragmin has a reduced adverse effect on platelet function and platelet adhesion, and thus only has a minimal effect on primary haemostasis^2-7.

Please refer to the SPC for a list of adverse events which may possibly be associated with Fragmin.

The risk of bleeding is dependent on dose. Most bleedings are mild. Severe bleedings have been reported, some cases with fatal outcome.

Heparin products can cause hypoaldosteronism which may result in an increase in plasma potassium. Rarely, clinically significant hyperkalaemia may occur particularly in patients with chronic renal failure and diabetes mellitus.

Long term treatment with heparain has been associated with a risk of osteoporosis. Although this has not been observed with dalteparin, the risk of osteoporosis cannot be excluded.

Paediatric population: Frequency, type and severity of adverse reactions in children are expected to be the same as in adults. The safety of long term dalteparin administration has not been established^2-7.